The current study showed the overexpression of PAK1 in human PCa and evaluated the PAK1 expression associated with clinicopathological features of patients with PCa, and provided the evidence regarding elucidation of potential mechanisms of mTOR inhibitor rapamycin and activator MYH1485 chemotherapy. Here, PAK1 is linked to posterior cortical atrophy.